355 related articles for article (PubMed ID: 32865701)
1. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study.
Wu Y; Hong K; Ruan L; Yang X; Zhang J; Xu J; Pan S; Ren L; Chen L; Huang C; Shang Y
Virol Sin; 2020 Dec; 35(6):768-775. PubMed ID: 32865701
[TBL] [Abstract][Full Text] [Related]
2. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.
Huang S; Shen C; Xia C; Huang X; Fu Y; Tian L
Med Sci Monit; 2020 Dec; 26():e928755. PubMed ID: 33264276
[TBL] [Abstract][Full Text] [Related]
4. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
6. Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19.
Ripoll JG; Tulledge-Scheitel SM; Stephenson AA; Ford S; Pike ML; Gorman EK; Hanson SN; Juskewitch JE; Miller AJ; Zaremba S; Ovrom EA; Razonable RR; Ganesh R; Hurt RT; Fischer EN; Derr AN; Eberle MR; Larsen JJ; Carney CM; Theel ES; Parikh SA; Kay NE; Joyner MJ; Senefeld JW
mBio; 2024 May; 15(5):e0040024. PubMed ID: 38602414
[TBL] [Abstract][Full Text] [Related]
7. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
[TBL] [Abstract][Full Text] [Related]
9. Use of convalescent serum reduces severity of COVID-19 in nonhuman primates.
Cross RW; Prasad AN; Borisevich V; Woolsey C; Agans KN; Deer DJ; Dobias NS; Geisbert JB; Fenton KA; Geisbert TW
Cell Rep; 2021 Mar; 34(10):108837. PubMed ID: 33662255
[TBL] [Abstract][Full Text] [Related]
10. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Devos T; Geukens T; Schauwvlieghe A; Ariën KK; Barbezange C; Cleeren M; Compernolle V; Dauby N; Desmecht D; Grimaldi D; Lambrecht BN; Luyten A; Maes P; Moutschen M; Romano M; Seyler L; Nevessignsky MT; Vandenberghe K; van Griensven J; Verbeke G; Vlieghe E; Yombi JC; Liesenborghs L; Verhamme P; Meyfroidt G
Trials; 2020 Nov; 21(1):981. PubMed ID: 33246499
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19.
Van Damme KFA; Tavernier S; Van Roy N; De Leeuw E; Declercq J; Bosteels C; Maes B; De Bruyne M; Bogaert D; Bosteels V; Hoste L; Naesens L; Maes P; Grifoni A; Weiskopf D; Sette A; Depuydt P; Van Braeckel E; Haerynck F; Lambrecht BN
Front Immunol; 2020; 11():596761. PubMed ID: 33329586
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq.
Rasheed AM; Fatak DF; Hashim HA; Maulood MF; Kabah KK; Almusawi YA; Abdulamir AS
Infez Med; 2020 Sep; 28(3):357-366. PubMed ID: 32920571
[TBL] [Abstract][Full Text] [Related]
13. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.
Lang-Meli J; Fuchs J; Mathé P; Ho HE; Kern L; Jaki L; Rusignuolo G; Mertins S; Somogyi V; Neumann-Haefelin C; Trinkmann F; Müller M; Thimme R; Umhau M; Quinti I; Wagner D; Panning M; Cunningham-Rundles C; Laubner K; Warnatz K
J Clin Immunol; 2022 Feb; 42(2):253-265. PubMed ID: 34893946
[TBL] [Abstract][Full Text] [Related]
14. Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors.
Ikegami S; Benirschke R; Flanagan T; Tanna N; Klein T; Elue R; Debosz P; Mallek J; Wright G; Guariglia P; Kang J; Gniadek TJ
Transfusion; 2020 Dec; 60(12):2962-2968. PubMed ID: 32840002
[TBL] [Abstract][Full Text] [Related]
15. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies.
Janssen M; Leo A; Wolf C; Stenzinger M; Bartenschlager M; Brandt J; Sauer S; Schmitt M; Dreger P; Schlenk RF; Denkinger CM; Müller-Tidow C
Int J Cancer; 2024 Aug; 155(4):618-626. PubMed ID: 38721724
[TBL] [Abstract][Full Text] [Related]
17. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
[TBL] [Abstract][Full Text] [Related]
18. No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity.
Nomoto H; Kutsuna S; Okuma K; Kuramitsu M; Tezuka K; Ikebe E; Saito S; Kinoshita N; Terada M; Endo M; Suzuki T; Miyazato Y; Nakamoto T; Inada M; Hamaguchi I; Ohmagari N
J Infect Chemother; 2021 Apr; 27(4):653-655. PubMed ID: 33487533
[TBL] [Abstract][Full Text] [Related]
19. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report.
Omrani AS; Zaqout A; Baiou A; Daghfal J; Elkum N; Alattar RA; Bakdach D; Abusriwil H; Mostafa AM; Alhariri B; Ambra N; Khatib M; Eldeeb AM; Merenkov Z; Fawzi Z; Hmissi SM; Hssain AA; Coyle PV; Alsoub H; Almaslamani MA; Alkhal A
J Med Virol; 2021 Mar; 93(3):1678-1686. PubMed ID: 32965715
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
